Nazira El-Hage1, Myosotys Rodriguez, Elizabeth M Podhaizer, Shiping Zou, Seth M Dever, Sarah E Snider, Pamela E Knapp, Patrick M Beardsley, Kurt F Hauser. 1. aDepartment of Pharmacology & Toxicology, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, Virginia, USA bDepartment of Microbiology & Immunology, Universidad Central del Caribe, Bayamón, Puerto Rico cDepartment of Anatomy & Neurobiology, Virginia Commonwealth University, Medical College of Virginia Campus dInstitute for Drug & Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia, USA.
Abstract
OBJECTIVE: We explored the antiviral therapeutic potential of ibudilast (AV411, MN-166) and its amino analog, AV1013. METHODS: We analyzed whether Ibudilast, a nonselective cyclic AMP phosphodiesterase inhibitor that has been used clinically in Asia for bronchial asthma, poststroke dizziness, and ocular allergies, and AV1013, attenuate HIV-1 replication and the synergistic interactions seen with opiate abuse-HIV-1 comorbidity in neuronal death and inflammation. RESULTS: AV411 and AV1013 inhibited replication by HIV-1 in microglia and significantly suppressed Tat ± morphine-induced tumor necrosis factor-α and MIF production, the activation of the nuclear factor-kappa B subunit p65, and neuronal death. AV411 and AV1013 prevented HIV-1 replication, and attenuated tumor necrosis factor-α and MIF release at concentrations of 100 nmol/l and 1 μmol/l, which are likely achievable at clinical doses. More importantly, co-exposure with morphine did not negate the inhibitory actions of AV411. CONCLUSION: Collectively, our data suggest that AV411 and its amino analog, AV1013, may be useful neuroprotective agents counteracting neurotoxicity caused by infected and activated glia, and implicate them as potential therapies for the management of HIV-associated neurocognitive disorders in an opioid-abusing population.
OBJECTIVE: We explored the antiviral therapeutic potential of ibudilast (AV411, MN-166) and its amino analog, AV1013. METHODS: We analyzed whether Ibudilast, a nonselective cyclic AMP phosphodiesterase inhibitor that has been used clinically in Asia for bronchial asthma, poststroke dizziness, and ocular allergies, and AV1013, attenuate HIV-1 replication and the synergistic interactions seen with opiate abuse-HIV-1 comorbidity in neuronal death and inflammation. RESULTS:AV411 and AV1013 inhibited replication by HIV-1 in microglia and significantly suppressed Tat ± morphine-induced tumor necrosis factor-α and MIF production, the activation of the nuclear factor-kappa B subunit p65, and neuronal death. AV411 and AV1013 prevented HIV-1 replication, and attenuated tumor necrosis factor-α and MIF release at concentrations of 100 nmol/l and 1 μmol/l, which are likely achievable at clinical doses. More importantly, co-exposure with morphine did not negate the inhibitory actions of AV411. CONCLUSION: Collectively, our data suggest that AV411 and its amino analog, AV1013, may be useful neuroprotective agents counteracting neurotoxicity caused by infected and activated glia, and implicate them as potential therapies for the management of HIV-associated neurocognitive disorders in an opioid-abusing population.
Authors: Yoonsang Cho; Gregg V Crichlow; Jon J Vermeire; Lin Leng; Xin Du; Michael E Hodsdon; Richard Bucala; Michael Cappello; Matt Gross; Federico Gaeta; Kirk Johnson; Elias J Lolis Journal: Proc Natl Acad Sci U S A Date: 2010-06-08 Impact factor: 11.205
Authors: Ren-Wu Chen; Anthony J Williams; Zhilin Liao; Changping Yao; Frank C Tortella; Jitendra R Dave Journal: Neurosci Lett Date: 2007-03-18 Impact factor: 3.046
Authors: Michael Bacher; Eberhard Weihe; Bernhard Dietzschold; Andreas Meinhardt; Helmut Vedder; Diethard Gemsa; Michael Bette Journal: Glia Date: 2002-03-15 Impact factor: 7.452
Authors: Supriya D Mahajan; Stanley A Schwartz; Thomas C Shanahan; Ram P Chawda; Madhavan P N Nair Journal: J Immunol Date: 2002-10-01 Impact factor: 5.422
Authors: Eduardo G Regis; Victor Barreto-de-Souza; Mariza G Morgado; Marcelo T Bozza; Lin Leng; Richard Bucala; Dumith C Bou-Habib Journal: Virology Date: 2010-01-20 Impact factor: 3.616
Authors: Ryan K Bachtell; Jermaine D Jones; Keith G Heinzerling; Patrick M Beardsley; Sandra D Comer Journal: Drug Alcohol Depend Date: 2017-08-31 Impact factor: 4.492
Authors: Sonia Mediouni; Maria Cecilia Garibaldi Marcondes; Courtney Miller; Jay P McLaughlin; Susana T Valente Journal: Front Microbiol Date: 2015-10-23 Impact factor: 5.640